DrugCite
Search

THERAPEUTIC RADIOPHARMACEUTICALS

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Therapeutic Radiopharmaceuticals Adverse Events Reported to the FDA Over Time

How are Therapeutic Radiopharmaceuticals adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Therapeutic Radiopharmaceuticals, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Therapeutic Radiopharmaceuticals is flagged as the suspect drug causing the adverse event.

Most Common Therapeutic Radiopharmaceuticals Adverse Events Reported to the FDA

What are the most common Therapeutic Radiopharmaceuticals adverse events reported to the FDA?

Diarrhoea
36 (2.63%)
Pyrexia
29 (2.12%)
Acute Myeloid Leukaemia
26 (1.9%)
Dehydration
22 (1.61%)
Decreased Appetite
20 (1.46%)
Pneumonia
20 (1.46%)
Leukopenia
17 (1.24%)
Stem Cell Transplant
17 (1.24%)
Anaemia
16 (1.17%)
Fatigue
16 (1.17%)
Failure To Anastomose
15 (1.1%)
Show More Show More
Lymphopenia
15 (1.1%)
Neutropenia
15 (1.1%)
Pulmonary Embolism
15 (1.1%)
Vomiting
15 (1.1%)
Platelet Count Decreased
13 (.95%)
Respiratory Failure
13 (.95%)
Drug Toxicity
12 (.88%)
Nausea
12 (.88%)
Sepsis
12 (.88%)
Wound Infection
12 (.88%)
Abdominal Pain
11 (.8%)
Dyspnoea
11 (.8%)
Thrombocytopenia
11 (.8%)
Dysphagia
10 (.73%)
Haemoglobin Decreased
10 (.73%)
Gastrooesophageal Reflux Disease
9 (.66%)
Myelodysplastic Syndrome
9 (.66%)
Pancytopenia
9 (.66%)
Hypokalaemia
8 (.59%)
Acute Lymphocytic Leukaemia
7 (.51%)
Dysarthria
7 (.51%)
Mucosal Inflammation
7 (.51%)
Radiation Injury
7 (.51%)
Septic Shock
7 (.51%)
Acute Respiratory Distress Syndrome
6 (.44%)
Atrial Fibrillation
6 (.44%)
Blood Sodium Decreased
6 (.44%)
Dizziness
6 (.44%)
Impaired Healing
6 (.44%)
Leukoencephalopathy
6 (.44%)
Malaise
6 (.44%)
Myocardial Infarction
6 (.44%)
Peripheral Motor Neuropathy
6 (.44%)
Urinary Tract Infection
6 (.44%)
White Blood Cell Count Decreased
6 (.44%)
Anastomotic Leak
5 (.37%)
Asthenia
5 (.37%)
Ataxia
5 (.37%)
Device Related Infection
5 (.37%)
Drug Ineffective
5 (.37%)
Febrile Neutropenia
5 (.37%)
Gastritis Erosive
5 (.37%)
General Physical Health Deteriorati...
5 (.37%)
Haematotoxicity
5 (.37%)
Hypoalbuminaemia
5 (.37%)
Hyponatraemia
5 (.37%)
Hypoxia
5 (.37%)
Interstitial Lung Disease
5 (.37%)
Lower Gastrointestinal Haemorrhage
5 (.37%)
Neutrophil Count Decreased
5 (.37%)
Oesophageal Stenosis
5 (.37%)
Oesophagitis
5 (.37%)
Peripheral Sensory Neuropathy
5 (.37%)
Pharyngeal Haemorrhage
5 (.37%)
Pneumonia Aspiration
5 (.37%)
Staphylococcal Infection
5 (.37%)
Abdominal Wall Abscess
4 (.29%)
Anal Abscess
4 (.29%)
Arthritis Reactive
4 (.29%)
Convulsion
4 (.29%)
Deafness
4 (.29%)
Death
4 (.29%)
Deep Vein Thrombosis
4 (.29%)
Female Genital Tract Fistula
4 (.29%)
Fluid Intake Reduced
4 (.29%)
Gastric Ulcer
4 (.29%)
Ileus
4 (.29%)
Infection
4 (.29%)
Leukaemia Recurrent
4 (.29%)
Metastases To Liver
4 (.29%)
Neuropathy Peripheral
4 (.29%)
Pain
4 (.29%)
Pneumonitis
4 (.29%)
Pulmonary Oedema
4 (.29%)
Refusal Of Treatment By Patient
4 (.29%)
Renal Failure
4 (.29%)
Respiratory Distress
4 (.29%)
Tetany
4 (.29%)
Transient Ischaemic Attack
4 (.29%)
Weight Decreased
4 (.29%)
Aphasia
3 (.22%)
B Precursor Type Acute Leukaemia
3 (.22%)
Back Pain
3 (.22%)
Blood Creatinine Increased
3 (.22%)
Bone Marrow Transplant
3 (.22%)
Cardiac Failure Congestive
3 (.22%)
Cellulitis
3 (.22%)
Colitis
3 (.22%)
Enterocolitis
3 (.22%)
Erythema Multiforme
3 (.22%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Therapeutic Radiopharmaceuticals, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Therapeutic Radiopharmaceuticals is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Therapeutic Radiopharmaceuticals

What are the most common Therapeutic Radiopharmaceuticals adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Therapeutic Radiopharmaceuticals, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Therapeutic Radiopharmaceuticals is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Therapeutic Radiopharmaceuticals According to Those Reporting Adverse Events

Why are people taking Therapeutic Radiopharmaceuticals, according to those reporting adverse events to the FDA?

Rectal Cancer
101
Breast Cancer
35
Oesophageal Carcinoma
23
Non-small Cell Lung Cancer
20
Hodgkins Disease
19
Glioblastoma
13
Show More Show More
Nasopharyngeal Cancer
10
Neoplasm
10
Metastases To Central Nervous Syste...
9
Glioblastoma Multiforme
8
Adenocarcinoma Pancreas
7
Gastric Cancer
7
Prostate Cancer
7
Pancreatic Carcinoma
6
Radiotherapy
5
Multiple Myeloma
5
Head And Neck Cancer
5
Non-small Cell Lung Cancer Stage Ii...
5
Cervix Carcinoma
5
Ewings Sarcoma
4
Acute Lymphocytic Leukaemia
4
Oesophageal Squamous Cell Carcinoma...
4
Pancreatic Carcinoma Non-resectable
4
Gastric Cancer Stage I
3
Product Used For Unknown Indication
3
Rhabdomyosarcoma
3
Allogenic Bone Marrow Transplantati...
3
Bladder Cancer
3
Palliative Care
3
Hepatic Neoplasm Malignant
2
Drug Use For Unknown Indication
2
Acute Lymphocytic Leukaemia Recurre...
2
Squamous Cell Carcinoma
2
Brain Neoplasm Malignant
2
Diffuse Large B-cell Lymphoma
2
Ill-defined Disorder
2
Neuroblastoma
2
Hypopharyngeal Cancer
2
Gastrointestinal Obstruction
2
Oesophageal Squamous Cell Carcinoma
2
Craniopharyngioma
2
Oesophageal Squamous Cell Carcinoma...
2
Myelodysplastic Syndrome
2
B-cell Lymphoma
2
Oropharyngeal Cancer Stage Iv
2
Prophylaxis
2
Back Pain
2
Medulloblastoma
2
Signet-ring Cell Carcinoma
1
Mesothelioma Malignant
1
Rectal Cancer Recurrent
1

Therapeutic Radiopharmaceuticals Case Reports

What Therapeutic Radiopharmaceuticals safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Therapeutic Radiopharmaceuticals. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Therapeutic Radiopharmaceuticals.